vistagen.com - Multiplikator forward rega marang pendapatan VTGN

Vistagen Therapeutics (VTGN) is developing unique, patent-protected anxiety sprays, which eliminates price competition. An innovative approach to olfactory receptors allows for the immediate mitigation of psychiatric disorders. The forward price-to-sales ratio demonstrates valuation dynamics, where the indicator value reaches 3.50. This chart is supplemented by data on partnerships with clinics that are accelerating clinical trials for new neuropreparations.
VTGN (VistaGen Therapeutics, Inc.): rincian analitis lan laporan miturut indikator

Vistagen Therapeutics (VTGN) develops CNS drugs using a model characterized by high R&D costs and easy sales scaling via contractors. The forward P/S valuation compares expected revenue with expansion rates, where stable values confirm market capture, while a sharp increase in this forward P/S valuation signals overpayment and the risk of multiple compression.